# Selinexor in Combination With Thalidomide and Dexamethasone in RRMM

> **NCT04891744** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Li Zheng** · enrollment: 48 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Thalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04891744
- **Lead sponsor:** Li Zheng
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-06
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2021-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04891744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04891744, "Selinexor in Combination With Thalidomide and Dexamethasone in RRMM". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04891744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*